These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma. Zeng SS; Yamashita T; Kondo M; Nio K; Hayashi T; Hara Y; Nomura Y; Yoshida M; Hayashi T; Oishi N; Ikeda H; Honda M; Kaneko S J Hepatol; 2014 Jan; 60(1):127-34. PubMed ID: 24012616 [TBL] [Abstract][Full Text] [Related]
4. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Yamashita T; Forgues M; Wang W; Kim JW; Ye Q; Jia H; Budhu A; Zanetti KA; Chen Y; Qin LX; Tang ZY; Wang XW Cancer Res; 2008 Mar; 68(5):1451-61. PubMed ID: 18316609 [TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinomas expressing 'stemness'-related markers: clinicopathological characteristics. Kim H; Park YN Dig Dis; 2014; 32(6):778-85. PubMed ID: 25376296 [TBL] [Abstract][Full Text] [Related]
6. Expression and role of epithelial cell adhesion molecule in dysplastic nodule and hepatocellular carcinoma. Bae JS; Noh SJ; Jang KY; Park HS; Chung MJ; Park CK; Moon WS Int J Oncol; 2012 Dec; 41(6):2150-8. PubMed ID: 22993038 [TBL] [Abstract][Full Text] [Related]
7. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. Terris B; Cavard C; Perret C J Hepatol; 2010 Feb; 52(2):280-1. PubMed ID: 20006402 [TBL] [Abstract][Full Text] [Related]
8. Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. Miltiadous O; Sia D; Hoshida Y; Fiel MI; Harrington AN; Thung SN; Tan PS; Dong H; Revill K; Chang CY; Roayaie S; Byrne TJ; Mazzaferro V; Rakela J; Florman S; Schwartz M; Llovet JM J Hepatol; 2015 Dec; 63(6):1368-77. PubMed ID: 26220754 [TBL] [Abstract][Full Text] [Related]
9. Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status. Shan YF; Huang YL; Xie YK; Tan YH; Chen BC; Zhou MT; Shi HQ; Yu ZP; Song QT; Zhang QY Med Oncol; 2011 Dec; 28(4):1012-6. PubMed ID: 20571936 [TBL] [Abstract][Full Text] [Related]
10. The EpCAM overexpression is associated with clinicopathological significance and prognosis in hepatocellular carcinoma patients: A systematic review and meta-analysis. Zhou L; Zhu Y Int J Surg; 2018 Aug; 56():274-280. PubMed ID: 29936198 [TBL] [Abstract][Full Text] [Related]
11. Keratin 19 protein expression is an independent predictor of survival in human hepatocellular carcinoma. Fatourou E; Koskinas J; Karandrea D; Palaiologou M; Syminelaki T; Karanikolas M; Felekouras E; Antoniou E; Manesis EK; Delladetsima J; Tiniakos D Eur J Gastroenterol Hepatol; 2015 Sep; 27(9):1094-102. PubMed ID: 26011233 [TBL] [Abstract][Full Text] [Related]
12. Cancer stem cells in hepatocellular carcinoma--an immunohistochemical study with histopathological association. Matthai SM; Ramakrishna B Indian J Med Res; 2015 Oct; 142(4):391-8. PubMed ID: 26609030 [TBL] [Abstract][Full Text] [Related]
13. Gamma-smooth muscle actin expression is associated with epithelial-mesenchymal transition and stem-like properties in hepatocellular carcinoma. Benzoubir N; Mussini C; Lejamtel C; Dos Santos A; Guillaume C; Desterke C; Samuel D; Bréchot C; Bourgeade MF; Guettier C PLoS One; 2015; 10(6):e0130559. PubMed ID: 26110787 [TBL] [Abstract][Full Text] [Related]
14. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Govaere O; Komuta M; Berkers J; Spee B; Janssen C; de Luca F; Katoonizadeh A; Wouters J; van Kempen LC; Durnez A; Verslype C; De Kock J; Rogiers V; van Grunsven LA; Topal B; Pirenne J; Vankelecom H; Nevens F; van den Oord J; Pinzani M; Roskams T Gut; 2014 Apr; 63(4):674-85. PubMed ID: 23958557 [TBL] [Abstract][Full Text] [Related]
15. The Role of Epithelial Cell Adhesion Molecule Cancer Stem Cell Marker in Evaluation of Hepatocellular Carcinoma. El-Kholy MA; Abu-Seadah SS; Hasan A; Elhussiny MEA; Abdelwahed MS; Hanbazazh M; Samman A; Alrashdi SA; Rashed ZF; Ashmawy D; Othman AE; Abdelaleem MF; Abo-Saif AIA; Abdel-Maqsoud RR; Attiah SM; Assiri ES; Nasr M; Ismail KA; Saad DZ; El-Mosely MM Medicina (Kaunas); 2024 May; 60(6):. PubMed ID: 38929532 [No Abstract] [Full Text] [Related]
16. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Hoshida Y; Nijman SM; Kobayashi M; Chan JA; Brunet JP; Chiang DY; Villanueva A; Newell P; Ikeda K; Hashimoto M; Watanabe G; Gabriel S; Friedman SL; Kumada H; Llovet JM; Golub TR Cancer Res; 2009 Sep; 69(18):7385-92. PubMed ID: 19723656 [TBL] [Abstract][Full Text] [Related]
17. Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM(+) AFP(+) hepatocellular carcinoma. Zhao X; Parpart S; Takai A; Roessler S; Budhu A; Yu Z; Blank M; Zhang YE; Jia HL; Ye QH; Qin LX; Tang ZY; Thorgeirsson SS; Wang XW Oncogene; 2015 Sep; 34(39):5095-104. PubMed ID: 25597408 [TBL] [Abstract][Full Text] [Related]
18. Molecular and histological correlations in liver cancer. Calderaro J; Ziol M; Paradis V; Zucman-Rossi J J Hepatol; 2019 Sep; 71(3):616-630. PubMed ID: 31195064 [TBL] [Abstract][Full Text] [Related]
19. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Kim H; Choi GH; Na DC; Ahn EY; Kim GI; Lee JE; Cho JY; Yoo JE; Choi JS; Park YN Hepatology; 2011 Nov; 54(5):1707-17. PubMed ID: 22045674 [TBL] [Abstract][Full Text] [Related]
20. Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM. Zen Y; Vara R; Portmann B; Hadzic N Histopathology; 2014 Apr; 64(5):671-82. PubMed ID: 24138022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]